Literature DB >> 4990592

Role of the sympathetic nervous system in daunomycin-induced arrhythmia in the monkey.

B Burka, E Herman, J Vick.   

Abstract

1. Infusion of daunomycin 50 mg/kg in the monkey consistently induced ventricular arrhythmias which were not influenced by bilateral vagotomy.2. A central sympathetic component to the arrhythmias was suggested because spinal transection, ganglionic blockade or bilateral stellate ganglionectomy prevented any alterations in the e.c.g.3. Bilateral adrenalectomy or splanchnic nerve section protected three of six animals. This source of catecholamines may not be necessary in every case to initiate the arrhythmia.4. Guanethidine was a relatively ineffective antiarrhythmic agent. Timing appears to be important with this agent.5. Pargyline, by monoamine oxidase inhibition or other mechanisms, significantly lowered the arrhythmic dose of daunomycin. Reserpine pretreatment, on the other hand, prevented any e.c.g. alterations following daunomycin.6. Phenoxybenzamine exerted significant protection which may be related to its cardiodepressant properties.7. Alterations in e.c.g. were seen in all (+)-propranolol pretreated animals, although the arrhythmic period was modified in two of three experiments. Racemic (+/-) propranolol, which exerts direct myocardium depression as well as beta-adrenoceptor blockade, was completely protective in four of five experiments. The results of the present experiments indicate that the sympathetic nervous system is intimately involved in the daunomycin arrhythmia.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4990592      PMCID: PMC1702608          DOI: 10.1111/j.1476-5381.1970.tb10358.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Studies on the cardiotoxicity of ouabain.

Authors:  A K Reynolds; M L Horne
Journal:  Can J Physiol Pharmacol       Date:  1969-02       Impact factor: 2.273

2.  Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.

Authors:  C Tan; H Tasaka; K P Yu; M L Murphy; D A Karnofsky
Journal:  Cancer       Date:  1967-03       Impact factor: 6.860

3.  Daunorubicin in acute myelocytic leukaemia.

Authors:  J S Malpas; R B Scott
Journal:  Lancet       Date:  1969-03-01       Impact factor: 79.321

4.  Cardiac toxicity of daunorubicin.

Authors:  A M Marmont; E Damasio; F Rossi
Journal:  Lancet       Date:  1969-04-19       Impact factor: 79.321

5.  Comparative cardiac toxicity of daunomycin in three rodent species.

Authors:  E H Herman; P Schein; R M Farmar
Journal:  Proc Soc Exp Biol Med       Date:  1969-04

6.  The effect of guanethidine on ouabain-induced ventricular arrhythmia in the cat.

Authors:  A Raines; D Moros; B Levitt
Journal:  Arch Int Pharmacodyn Ther       Date:  1968-08

7.  The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog.

Authors:  R G Shanks
Journal:  Br J Pharmacol Chemother       Date:  1966-02

8.  Some aspects of the anti-arrhythmic activity of reserpine.

Authors:  F Ciofalo; B Levitt; J Roberts
Journal:  Br J Pharmacol Chemother       Date:  1966-10

9.  Optical isomers of propranolol.

Authors:  R Howe; R G Shanks
Journal:  Nature       Date:  1966-06-25       Impact factor: 49.962

10.  Alteration of ouabain taxicity by cardiac denervation.

Authors:  L D Boyajy; C B Nash
Journal:  Toxicol Appl Pharmacol       Date:  1966-09       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.